MarketPulse

Phase 3 trials

31 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio's Verekitug Shows Strong Phase 2 Results in Nasal Polyp Treatment

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.
UPBPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Celldex

Celldex's Barzolvolimab Shows Durable Efficacy in Retreatment Trial

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.
CLDXbarzolvolimabcold urticaria
BenzingaBenzinga··Prnewswire

Psychedelic Drug Developers Entering Final Testing Phase for Mental Health Treatments

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.
ATAIDFTXGHRSLBRXpsychedelic biotechnologyPhase 3 trials
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
BenzingaBenzinga··Vandana Singh

Viking Therapeutics Climbs on Competitive Positioning in Obesity Drug Race

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.
LLYNVORHHBYVKTXPhase 3 trialsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Mereo BioPharma Over Failed Clinical Trials

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trial Disclosures

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.
MREOsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials
BenzingaBenzinga··Vandana Singh

European Regulators Approve GSK's Biannual Asthma Drug Targeting Type 2 Inflammation

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.
GSKPhase 3 trialssevere asthma
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Investors Face April Deadline in Securities Lawsuit Over Failed Trials

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trial Disclosures

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors claim the company concealed negative trial results.
MREOsecurities fraudclass action lawsuit